#rtCGM
LightNews LightNews
newsmedical.bsky.social
Can 3 years of continuous glucose monitoring do more than control blood sugar? This study found a surprising drop in kidney risk markers for high-risk type 2 diabetes patients. 👀🩺

Read more: www.news-medical.net/news/2026101... #Diabetes #KidneyHealth #Health @jamanetworkopen.com
Researchers followed glucose monitor users for three years and found a possible kidney benefit
A study of more than 25,000 analytical group assignments involving high-risk adults with type 2 diabetes found that sustained real-time continuous glucose monitoring (rtCGM) was associated with substa...
www.news-medical.net
October 12, 2026 at 6:05 AM
jamanetworkopen.com
📈 In adults with #Type2Diabetes who had poor glycemic control or recent hypoglycemia, sustained use of real-time #ContinuousGlucoseMonitoring was associated with durable reductions in hemoglobin A1c over 3 year.

ja.ma/4eiNHe0
Six graphs (A-F) show HbA1c (%), UACR (mg/g), and eGFR (mL/min/1.73 m²) trends over 3 years for Control (dark) vs. rtCGM (orange). HbA1c: rtCGM shows a steeper, sustained drop vs. Control. UACR: Unadjusted rtCGM higher, weighted similar to Control. eGFR: rtCGM starts lower and declines more.
October 8, 2026 at 4:50 AM
adapubs.bsky.social
In #T2D on insulin and #hemodialysis, %TBR was low & not affected by #rtCGM. Compared to capillary glucose testing, %TIR, mean glucose and %TAR improved during the #rtCGM intervention.

Read here ➡️ doi.org/10.2337/dc26-0404
This image is an infographic about a clinical trial on real-time continuous glucose monitoring (rtCGM) for people with type 2 diabetes and end-stage kidney failure. It includes sections on the study's objective, outcomes, design, and conclusions. Bars and graphs show glycemic ranges, with multicolored sections representing the different ranges. The trial duration is noted as 180 days, with specific phases like randomization and washout. The data is presented clearly with labels and color coding for readability.
July 30, 2026 at 8:55 PM
adapubs.bsky.social
Real-world evidence from explorative analysis: #fearofhypoglycemia and #perceptionofhypoglycemia are not correlated with #CGM metrics in adults with #type1diabetes on #rtCGM or #HCL for one year.

Read here ➡️ doi.org/10.2337/dc26-0763
The image is an infographic titled "No Correlation Between Fear or Perceived Frequency of Hypoglycemia and Time in Hypoglycemia or Other CGM Metrics in Adults With Type 1 Diabetes Using Technology." It includes two main sections: "Study Population and Design" and "Findings." The "Study Population and Design" section describes two trial groups, ALERTT1 and IN RANGE, with sample sizes and timelines for starting technology use. The "Findings" section features a scatterplot indicating no significant correlation and a note about a lack of association between fear of hypoglycemia and CGM metrics. A purple box highlights the absence of correlation between fear or perception of hypoglycemia and CGM metrics.
July 28, 2026 at 1:20 PM
health-europe-de.bsky.social
🤰 Schwangere Frauen mit #Diabetes können ihren #Blutzucker mit automatischen #CGM-Systemen ebenso gut überwachen wie mit der bisher üblichen Selbstmessung, wie eine Studie der Universitätsklinik für Frauenheilkunde des Inselspitals, Universitätsspital Bern, und @unibe.ch ‪belegt. #Schwangerschaft
Diabetes in der Schwangerschaft: rtCGM gleichauf mit Selbsttest
Forschende der Universitätsklinik für Frauenheilkunde des Inselspitals, Universitätsspital Bern und der Universität Bern haben in einer aktuellen Studie untersucht, ob die kontinuierliche Echtzeit-Bl...
healthcare-in-europe.com
June 5, 2025 at 9:25 AM
diabsite.bsky.social
GlucoMen® iCan: Neues CGM-System für Menschen mit #Diabetes. Exklusive Vertriebsvereinbarung für neues rtCGM-System zwischen A.Menarini Diagnostics und Sinocare. www.diabsite.de/aktuelles/na...
January 6, 2025 at 7:18 PM
tee-tea-cha.bsky.social
👉 Die #App des #Dexcom #G7 Sensors stürzt unter #Android manchmal ab und verlangt eine #Neuinstallation.😠 Wie man statt einer Neuinstallation die App ohne #Datenverlust schnell wieder zum Laufen bringt, erkläre ich hier: datenstrand.de/2024/07/dexc...

#Workaround #Diabetes #rtcgm #Sensor
Dexcom G7: Android App-Absturz und Workaround statt Neuinstallation - Datenstrand.de
Du bist Diabetiker und nutzt den G7-Sensor von Dexcom mit der Smartphone-App auf einem Android-Gerät? Dann wirst du vermutlich auch schon von Zeit zu Zeit einen App-Absturz erlebt haben, der in der Me...
datenstrand.de
July 8, 2024 at 7:40 PM
rcatanho.bsky.social
Monitorización continua de la glucosa en tiempo real no mejora las variables de la diabetes gestacional, aunque las pacientes expresan mayor preferencia por el equipo, por lo que podría simplificar el control de la diabetes #CGM #gestationaldiabetes www.thelancet.com/journals/lan...
Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial
Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a higher preference for the rtCGM device. This finding su...
www.thelancet.com
July 3, 2025 at 6:13 AM
thelancetendo.bsky.social
Continuous glucose monitoring in the management of #gestational #diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial www.thelancet.com/journals/lan... #CGM #GDM
#OpenAccess

#MedSky #EndoSky #WomensHealthSky
Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial
Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a higher preference for the rtCGM device. This finding su...
www.thelancet.com
June 25, 2025 at 9:55 AM
thelancetendo.bsky.social
Continuous glucose monitoring in the management of #gestational #diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial thelancet.com/journals/lan...
#CGM #GDM
#OpenAccess

#MedSky #EndoSky #WomensHealthSky
Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial
Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a higher preference for the rtCGM device. This finding su...
thelancet.com
June 12, 2025 at 2:56 PM
thelancetendo.bsky.social
New Research:
Continuous glucose monitoring in the management of #gestational #diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial thelancet.com/journals/lan...
#CGM #GDM #pregnancy
#OpenAccess

#MedSky #EndoSky #WomensHealthSky
Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial
Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a higher preference for the rtCGM device. This finding su...
thelancet.com
May 26, 2025 at 10:38 PM
mobiflip.de
Apple Watch & Dexcom G7: Diabetes-Management jetzt per Direktverbindung https://www.mobiflip.de/shortnews/apple-watch-dexcom-g7-diabetes-management-jetzt-per-direktverbindung/
Apple Watch & Dexcom G7: Diabetes-Management jetzt per Direktverbindung
DexCom, Inc. hat bekannt gegeben, dass das Dexcom G7 System zur kontinuierlichen Glukosemessung in Echtzeit (rtCGM) ab sofort in Deutschland, Österreich und der Schweiz direkt mit der Apple Watch verbunden werden kann.
www.mobiflip.de
August 28, 2024 at 7:04 AM
idbravotobar.bsky.social
Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial - The Lancet Diabetes & Endocrinology www.thelancet.com/journals/lan...
Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial
Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a higher preference for the rtCGM device. This finding su...
www.thelancet.com
May 27, 2025 at 9:20 PM